# P-1732. Antifungal Susceptibility Patterns of Major Candida Species Isolated From 1390 Bloodstream Infections in Costa Rica: A 12-Year Experience

**Authors:** Juan Villalobos Vindas, Jose A Castro Cordero, Elvira Segura Retana, Carlos Ramírez Valverde, Randall G León Solís, Saúl Quirós Cárdenas, Heylin Estrada Murillo, Alvaro A Aviles Montoya, Laura Villalobos González

PMC · DOI: 10.1093/ofid/ofaf695.1903 · Open Forum Infectious Diseases · 2026-01-11

## TL;DR

This study analyzed antifungal resistance in Candida species from bloodstream infections in Costa Rica over 12 years, finding high resistance in C. parapsilosis to certain drugs.

## Contribution

The study provides the first detailed 12-year analysis of antifungal susceptibility patterns of major Candida species in Costa Rica.

## Key findings

- C. parapsilosis showed high resistance to fluconazole (59.4%) and voriconazole (20.2%).
- Amphotericin B maintained excellent activity against all Candida species tested.
- Echinocandins were highly effective against most species except C. glabrata.

## Abstract

Candida species represent 80% of nosocomial fungal infections, with candidemia being the most frequent invasive disease. In Latin America, Candida resistance is generally low, but information from Central America is scarce. We aimed to describe antifungal susceptibility of Candida species isolated from bloodstream infections at two national adult hospitals in Costa Rica from 2012 to 2023.

This retrospective study analyzed the first isolate from candidemia episodes caused by C. albicans, C. tropicalis, C. parapsilosis, and C. glabrata with available susceptibility results. Testing used VITEK 2 system. Interpretation followed CLSI M27M44S-Ed3 guidelines. Amphotericin B susceptibility was defined as MIC ≤1μg/ml. Differences between species were assessed using Fisher's exact test, and temporal trends with chi-square test.

We analyzed 1,390 isolates: C. parapsilosis 689 (49.6%), C. albicans 448 (32.2%), C. tropicalis 131 (9.4%), and C. glabrata 122 (8.8%). Fluconazole susceptibility was high in C. albicans (97.1%) and C. tropicalis (96.2%), but lower in C. parapsilosis (40.6%, p< 0.001). C. glabrata isolates were predominantly susceptible-dose dependent (96.1%). Voriconazole showed high activity against C. albicans (98.7%) and C. tropicalis (96.9%), but resistance in C. parapsilosis (20.2%). Amphotericin B maintained excellent activity against all species (98.7% overall). Echinocandins demonstrated high efficacy against C. albicans, C. tropicalis, and C. parapsilosis (≥99%), but reduced activity against C. glabrata (caspofungin 41.3% susceptible, micafungin with 70.6% intermediate and 29.4% resistant). No significant temporal trends in susceptibility were observed over the 12-year period.

Our findings reveal significant azole resistance in C. parapsilosis, particularly to fluconazole (59.4%) and voriconazole (20.2%). Amphotericin B maintains excellent activity against all species. Echinocandins remain highly effective against most Candida species except C. glabrata. These patterns have important implications for empirical antifungal therapy selection in our region.

All Authors: No reported disclosures

## Linked entities

- **Chemicals:** fluconazole (PubChem CID 3365), voriconazole (PubChem CID 71616), amphotericin B (PubChem CID 1972), caspofungin (PubChem CID 16119814), micafungin (PubChem CID 477468)
- **Diseases:** candidemia (MONDO:0044070)
- **Species:** Candida albicans (taxon 5476), Candida tropicalis (taxon 5482)

---
Source: https://tomesphere.com/paper/PMC12791999